[1] SU H. Antihypertensive agents may increase new-onset diabetes. China Pharm News(中国医药报). 2009-7-14(B02). [2] LIU W, JIA A Q. The application trend and economic analysis of antihypertensive drugs. Chin Pharm J(中国药学杂志),2003,38(3):225-226. [3] WILKINS R. New drugs for the treatment of hypertension. Ann Intern Med, 1959,50(1): 1-12. [4] WANG R Q, LI Y N, QIN X J. The effect of antihypertensive drugs on glucose metabolism and its enlightenment to clinical rational use of drug. Chin J Pharm acovigilance(中国药物警戒),2009,6(5):298-301. [5] LIAO W Q, CHEN P Y. Bayesian mixed treatment comparisons and implementation using WinBUGS. Chin J New Drugs(中国新药杂志),2010,19 (24) :2244-2248. [6] SCHULZ K F, ALTMAN D G, MOHER D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Ann Intern Med, 2010, 152(11): 726-732. [7] LIAO W Q. Simulation studies on multiple treatments meta-analysis and indirect comparisons. Guangzhou: Southern Medical University, 2011. [8] YUSUF S, DIENER H C, SACCO R L, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med,2008, 359(12):1225-1237. [9] MCMURRAY J J, HOLMAN R R. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med, 2010, 362(16):1477-1490. LITHELL H, HANSSON L, SKOOG I, et al. The study on cognition and prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hyperten,2003, 21(5):875-886. GRANGER C B, MCMURRAY J J, YUSUF S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors:The CHARM-Alternative trial. Lancet, 2003, 362(9386):772-776. YUSUF S, PFEFFER M A, SWEDBERG K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARMPreserved Trial. Lancet,2003, 362(9386):777-781. YUSUF S, TEO K. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in highrisk patients intolerant to angiotensin-converting enzyme inhibitors: A randomized controlled trial. Lancet, 2008,372(9644):1174-1183. SAWADA T, YAMADA H, DAHLOF B, et al. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J, 2009,30(20):2461-2469. OGIHARA T, NAKAO K, FUKUI T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan antihypertensive survival evaluation in Japan trial. Hypertension, 2008,51(2):393-398. JULIUS S, KJELDSEN S E, WEBER M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet, 2004,363(9426):2022-2031. LINDHOLM L H, IBSEN H, DAHL F B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet, 2002,359(9311):1004-1010. LINDHOLM L H, PERSSON M, ALAUPOVIC P, et al. Metabolic outcome during 1 year in a newly-detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profi le in a North of Sweden Efficacy Evaluation (ALPINE Study). J Hypertens, 2003, 21: 1563-1574. DREAM TRIAL INVESTIGATORS, BOSCH J, YUSUF S, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med, 2006,355(15):1551-1562. FOX K M. European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003,362(9386):782-788. VERMES E, DUCHARME A, BOURASSA M G, et al. Studies of left ventricular dysfunction. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the studies of left ventricular dysfunction (SOLVD). Circulation,2003,107(9):1291-1296. YUSUF S, GERSTEIN H, HOOGWERF B, et al. Ramipril and the development of diabetes. JAMA, 2001,286: 1882-1885. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med, 2004,351(20):2058-2068. HANSSON L, LINDHOLM L H, NISKANEN L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The captopril prevention project (CAPPP) randomized trial. Lancet, 1999,353 (9153):611-616. JANDELEIT-DAHM K A, TIKELLIS C, REID C M, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens, 2005,23: 463-473. THORNLEY-BROWN D, WANG X, WRIGHT J T J R, et al. Diff ering eff ects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Arch Intern Med,2006, 166(7):797-805. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002,288(23):2981-2997. LIU L, ZHANG Y, LIU G, et al. The Felodipine Event Reduction (FEVER) study: A randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens, 2005, 23(12): 2157-2172. BROWN M J, PALMER C R, CASTAIGNE A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet, 2000,356(9227): 366-372. DAHL F B, SEVER P S, POULTER N R, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofl umethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomized controlled trial. Lancet,2005, 366(9489): 895-906. PEPINE C J, HANDBERG E M, COOPER-DEHOFF R M, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA,2003,290(21): 2805-2816. WILHELMSEN L, BERGLUND G, ELMFELDT D, et al. Beta-blockers versus diuretics in hypertensive men: Main result from the HAPPHY trial. J Hypertens, 1987, 5(5): 560-572. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results. BMJ, 1992, 304(6824): 405-412. FLETCHER A, AMERY A, BIRKENHAGER W, et al. Risks and benefi ts in the trial of the European Working Party on High Blood Pressure in the Elderly. J Hypertens, 1991, 9(3): 225-230. SAVAGE P H, PRESSEL S L, CURB D, et al. Infl uence of long-term, lowdose, diuretic-based antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Arch Intern Med,1998,158(7): 741-751. GENG D F, JIN D M, WU W, et al. Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: A meta-analysis of 59,862 patients. Int J Cardiol(国际心脏病学杂志),2012,155(2):236-242. GENG D F, JIN D M, WU W, et al. Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: A meta-analysis of 72,128 patients. Int J Cardiol (2012), doi:10. 1016/j. ijcard. 2012. 06. 125. TOCCI G,PANENI F, PALANO F, et al. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: A meta-analysis of placebo-controlled clinical trials. Am J Hyperten Sion,2011,24(5):582-590. American Diabetes Association. Position statement: Diagnosis and classification of diabetes mellitus. Diabetes Care, 2004,27 (suppl 1):5-10.